Cure8 research brief
A pooled analysis of cardiovascular risk tied to advanced IBD therapies could affect treatment decisions and monitoring plans because some immune-targeted drugs have been linked to cardiovascular safety concerns in other diseases.
Adults with Crohn’s disease or ulcerative colitis on or considering biologics/small molecules; gastroenterologists and IBD clinicians; drug-safety researchers.
The article pools evidence from randomized trials and possibly observational studies to compare cardiovascular event rates across advanced IBD treatments. It focuses on major cardiovascular events as an outcome and uses standard meta-analytic methods (risk-of-bias tools and sparse-data approaches are cited).
The paper appears to be a broad safety synthesis rather than a new randomized trial. It references prior meta-analyses and trials of biologics and small molecules in IBD and related immune-mediated diseases. It likely summarizes event definitions, trial durations, and heterogeneity across studies, which affect how findings should be interpreted.
This is a systematic review and meta-analysis (journal article). The extracted text and references show the authors used established meta-analytic methods and prior trial data; review the full article for specific drug-class findings, definitions of major adverse cardiovascular events, and study-level limitations before drawing clinical conclusions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Respiratory diseases (COPD, asthma, bronchiectasis) and IBD appear to occur together more often than expected. If you have IBD, especially Crohn’s, you may be at higher risk for some obstructive lung diseases, and people...
This meta-analysis suggests people with IBD—especially those with Crohn’s disease—have a modestly increased risk of stroke. That makes cardiovascular risk assessment and prevention potentially more important for people...
PSC is rare in the general population but substantially more common in people with IBD, particularly ulcerative colitis, and it raises long-term hepatobiliary risks including cholangiocarcinoma—so knowing how often PSC...
